sorafenib has been researched along with Carcinoma, Transitional Cell in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, K; Han, HJ; Jung, H; Kim, JH; Lee, JY; Yoon, HY; Yoon, KA | 1 |
| Maeda, S; Momoi, Y; Yokota, S; Yonezawa, T | 1 |
| Arapi, V; Franzén, B; Hååg, P; Holmsten, K; Lewensohn, R; Sandström, P; Shah, CH; Ullén, A; Viktorsson, K | 1 |
| Ahn, DH; Bae, K; Han, HJ; Kim, JH; Moon, JS; Yoon, KA | 1 |
| Deshpande, H; Donadio, A; Hurwitz, ME; Kelly, WK; Markowski, P; Mehnert, JM; Mortazavi, A; Patel, J; Petrylak, DP; Stein, MN; Yao, X | 1 |
| Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
| DiPaola, R; Dreicer, R; Eleff, M; Li, H; Roth, BJ; Stein, M; Wilding, G | 1 |
1 review(s) available for sorafenib and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
3 trial(s) available for sorafenib and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Sorafenib; Survival Analysis; Urologic Neoplasms | 2018 |
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Paclitaxel; Pain Measurement; Phenylurea Compounds; Quality of Life; Sorafenib; Urinary Bladder Neoplasms | 2015 |
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Transitional Cell; Disease-Free Survival; Drug Evaluation; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retreatment; Sorafenib; Urinary Bladder Neoplasms | 2009 |
5 other study(ies) available for sorafenib and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Culture Techniques; Cells, Cultured; Dogs; Female; Mice; Mutation; Proto-Oncogene Proteins B-raf; Sorafenib; Urologic Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Dog Diseases; Dogs; Fibrosarcoma; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Rodent Diseases; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome.
Topics: Biomarkers; Carcinoma, Transitional Cell; Extracellular Vesicles; Humans; Sorafenib; Toll-Like Receptor 3; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Circulating Tumor DNA; Dog Diseases; Dogs; Female; Lymphatic Metastasis; Mutation; Proto-Oncogene Proteins B-raf; Sorafenib; Treatment Outcome; Urethral Neoplasms | 2021 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |